swissmedic

Summary report on authorisation dated 10 August 2026

MenQuadfi® (active substance: polysaccharides of *Neisseria meningitidis* groups A, C, W-135 and Y conjugated to tetanus toxoid carrier protein)

Indication extension in Switzerland: 17 February 2026

Solution for injection for active immunisation against invasive meningococcal disease in children from 6 weeks of age and adults

About the medicinal product

The active substance in the vaccine MenQuadfi comprises polysaccharides of *Neisseria meningitidis* groups *A, C, W-135* and *Y* which are bound to the tetanus toxoid carrier protein. MenQuadfi is available as a ready-to-use solution for injection in single doses.

MenQuadfi is a quadrivalent vaccine used for the prevention of (active immunisation against) invasive meningococcal disease caused by groups A, C, W and Y of the *Neisseria meningitidis* bacteria.

MenQuadfi was first authorised by Swissmedic on 5 October 2022 for active immunisation against invasive meningococcal disease in children from 12 months of age and adults.

The current indication extension means that MenQuadfi can now also be used for active immunisation against invasive meningococcal disease in children from as young as 6 weeks of age.

The indication extension for MenQuadfi was authorised as part of the joint initiative of the Access Consortium.

This joint initiative is a collaborative project between the drug regulatory authorities in Australia (Therapeutic Goods Administration, TGA), Canada (Health Canada, HC), Singapore (Health Sciences Authority, HSA), the United Kingdom (Medicines & Healthcare products Regulatory Agency, MHRA), and Swissmedic. The joint initiative coordinates the assessment of authorisation applications for preparations with new active substances and indication extensions for these preparations that have been submitted in at least two of the five countries.

The application for indication extension for MenQuadfi was submitted to the drug regulatory authorities in Australia (Therapeutic Goods Administration, TGA), Canada (Health Canada, HC), Singapore (Health Sciences Authority, HSA) and Switzerland. Each country assessed a part of the application and then shared and discussed the results. At the end of the process, each authority made its own, independent decision on whether to approve the indication extension.

Swissmedic considered the assessments of the foreign reference authorities in its decision.

The requirements for issuing a comprehensive SwissPAR (Swiss Public Assessment Report) and a Summary report on authorisation based on this SwissPAR have not been fulfilled. Swissmedic refers to the authorisation of the foreign reference authorities.

Further details of the Access joint initiative are published on the Swissmedic website: Access Consortium (swissmedic.ch).

Further information on the medicinal product

Information for healthcare professionals: Information for healthcare professionals MenQuadfi®

Healthcare professionals can answer any further questions.

The date of revision of this text corresponds to that of the SwissPAR. New information concerning the authorised medicinal product in question will not be incorporated into the Summary report on authorisation.

Swissmedic monitors medicinal products authorised in Switzerland. Swissmedic initiates the necessary action in the event of newly discovered adverse drug reactions or other safety-relevant signals. New findings that could impair the quality, efficacy, or safety of this medicinal product are recorded and published by Swissmedic. If necessary, the medicinal product information is adapted.